Entera Bio (ENTX) Operating Income (2019 - 2026)

Entera Bio (ENTX) has reported Operating Income for 8 consecutive years, with -$3.5 million the latest figure, recorded in Q1 2026.

• Quarterly Operating Income fell 38.08% year-over-year to -$3.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$12.6 million (down 24.18% YoY) and the FY2025 annual result came in at -$11.5 million, down 20.28% from the prior year.
• Operating Income slipped to -$3.5 million in Q1 2026 per ENTX's latest filing, from -$3.0 million in the prior quarter.
• Over the last five years, Operating Income for ENTX reached as high as -$2.0 million in Q4 2023 and fell as low as -$3.8 million in Q1 2022.
• A 5-year average of -$2.7 million and a median of -$2.7 million in 2025 frame the typical range for Operating Income.
• Annual changes were most pronounced in 2022 — Operating Income slumped 63.96% — and 2023, when it soared 42.32%.
• Year by year, Operating Income stood at -$3.1 million in 2022, then surged by 36.02% to -$2.0 million in 2023, then dropped by 19.05% to -$2.3 million in 2024, then fell by 29.61% to -$3.0 million in 2025, then slipped by 16.84% to -$3.5 million in 2026.
• According to Business Quant data, Operating Income over the past three periods registered -$3.5 million, -$3.0 million, and -$3.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.